CN111032630A - 一种化合物，其药物组合物及其用途及应用 - Google Patents

一种化合物，其药物组合物及其用途及应用 Download PDF

Info

Publication number
CN111032630A
CN111032630A CN201880053263.5A CN201880053263A CN111032630A CN 111032630 A CN111032630 A CN 111032630A CN 201880053263 A CN201880053263 A CN 201880053263A CN 111032630 A CN111032630 A CN 111032630A
Authority
CN
China
Prior art keywords
group
compound
alkyl
amino
radical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880053263.5A
Other languages
English (en)
Other versions
CN111032630B (zh
Inventor
赵涛
魏栋
李敏
金孟夑
郑哲雄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Hanmi Pharmaceutical Co Ltd
Original Assignee
Beijing Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Hanmi Pharmaceutical Co Ltd filed Critical Beijing Hanmi Pharmaceutical Co Ltd
Publication of CN111032630A publication Critical patent/CN111032630A/zh
Application granted granted Critical
Publication of CN111032630B publication Critical patent/CN111032630B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

提供一种具有蛋白激酶抑制剂活性的嘧啶酰氨类化合物以及含有该化合物的药物组合物，提供该化合物的用途及应用。提供选自于由下述通式(Ⅰ)所示的化合物、其立体异构体、其互变异构体、其药学上可接受的盐、其溶剂化物和前药所组成的组中。上述化合物对JAK家族激酶和SYK激酶具有良好的抑制活性，因此可作为JAK家族激酶和SYK激酶抑制剂，有效应用于JAK家族激酶和SYK激酶相关疾病的预防或者治疗应用中。

Description

PCT国内申请，说明书已公开。

Claims (16)

  1. PCT国内申请，权利要求书已公开。
CN201880053263.5A 2017-08-18 2018-08-17 一种化合物，其药物组合物及其用途及应用 Active CN111032630B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017107133898 2017-08-18
CN201710713389 2017-08-18
PCT/CN2018/101128 WO2019034153A1 (zh) 2017-08-18 2018-08-17 一种化合物，其药物组合物及其用途及应用

Publications (2)

Publication Number Publication Date
CN111032630A true CN111032630A (zh) 2020-04-17
CN111032630B CN111032630B (zh) 2022-12-16

Family

ID=65361785

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880053263.5A Active CN111032630B (zh) 2017-08-18 2018-08-17 一种化合物，其药物组合物及其用途及应用

Country Status (6)

Country Link
US (1) US20200172529A1 (zh)
EP (1) EP3670500A4 (zh)
JP (1) JP2020531574A (zh)
KR (1) KR20200041954A (zh)
CN (1) CN111032630B (zh)
WO (1) WO2019034153A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114269736A (zh) * 2020-11-26 2022-04-01 深圳铂立健医药有限公司 一种酰胺化合物、药物组合物及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102083800A (zh) * 2008-06-27 2011-06-01 阿维拉制药公司 杂芳基化合物和其用途
CN102740847A (zh) * 2009-12-29 2012-10-17 阿维拉制药公司 杂芳基化合物和其用途
WO2013169401A1 (en) * 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
CN103501612A (zh) * 2011-05-04 2014-01-08 阿里亚德医药股份有限公司 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
CN104262328A (zh) * 2013-09-18 2015-01-07 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8148391B2 (en) * 2006-10-23 2012-04-03 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
CA2693594A1 (en) * 2007-07-17 2009-01-22 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as pkc inhibitors
KR101623997B1 (ko) * 2008-04-16 2016-05-24 포톨라 파마슈티컬스, 인코포레이티드 ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노－피리미딘－５－일－카르복스아미드
TWI478922B (zh) * 2008-12-08 2015-04-01 Gilead Connenticut Inc 作為脾臟酪胺酸激酶（Ｓｙｋ）抑制劑之咪唑並吡化合物
CN102265441B (zh) * 2008-12-31 2014-09-03 圣戈本陶瓷及塑料股份有限公司 sofc阴极以及用于共烧制的电池以及堆叠体的方法
LT2975042T (lt) * 2010-06-23 2019-01-25 Hanmi Science Co., Ltd. Naujieji kondensuoti pirimidino dariniai, skirti tirozino kinazės aktyvumo slopinimui

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102083800A (zh) * 2008-06-27 2011-06-01 阿维拉制药公司 杂芳基化合物和其用途
CN102740847A (zh) * 2009-12-29 2012-10-17 阿维拉制药公司 杂芳基化合物和其用途
CN103501612A (zh) * 2011-05-04 2014-01-08 阿里亚德医药股份有限公司 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
WO2013169401A1 (en) * 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
CN104262328A (zh) * 2013-09-18 2015-01-07 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114269736A (zh) * 2020-11-26 2022-04-01 深圳铂立健医药有限公司 一种酰胺化合物、药物组合物及其应用
CN114269736B (zh) * 2020-11-26 2024-02-02 科辉智药(深圳)新药研究中心有限公司 一种酰胺化合物、药物组合物及其应用

Also Published As

Publication number Publication date
JP2020531574A (ja) 2020-11-05
EP3670500A4 (en) 2020-12-16
WO2019034153A1 (zh) 2019-02-21
US20200172529A1 (en) 2020-06-04
EP3670500A1 (en) 2020-06-24
CN111032630B (zh) 2022-12-16
KR20200041954A (ko) 2020-04-22

Similar Documents

Publication Publication Date Title
JP5977779B2 (ja) ２−（２，４，５−置換−アニリノ）ピリミジン化合物
EP3129371B1 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
BR112021007679A2 (pt) inibidores de tyk2 e seus usos
CN111032630B (zh) 一种化合物，其药物组合物及其用途及应用
JP5124471B2 (ja) 置換二環式ピリミドン誘導体
EP3868750A1 (en) Modulators of ror-gamma
EP3209665B1 (en) Substituted pyrrolotriazine amine compounds as pi3k inhibitors
CN112823005A (zh) 吡咯并嘧啶itk抑制剂
JP2010523522A (ja) Ｊａｋ３阻害剤としてのピロロピリミジン誘導体
JP7248256B2 (ja) Ｊａｋキナーゼ阻害剤及びその調製方法、並びにその医薬分野での使用
KR20200090636A (ko) 피롤로피리미딘 유도체 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
CN114401955A (zh) 细胞周期蛋白依赖性激酶的抑制剂
WO2020150545A1 (en) Pyrazole derivatives as modulators of the wnt/b-catenin signaling pathway
AU2018208516A1 (en) Novel amino-imidazopyridine derivatives as Janus kinase inhibitors and pharmaceutical use thereof
WO2016196910A1 (en) Compounds for the modulation of myc activity
WO2016127455A1 (zh) 嘧啶衍生物、细胞毒性剂、药物组合物及其应用
TW202023548A (zh) 新穎噻唑衍生物以及其藥用可接受鹽類
TW202024072A (zh) 作為PI3Kβ抑制劑的1,5-二氮雜萘-4(1H)-酮衍生物
CN112250666B (zh) 取代的嘧啶类化合物及其用途
WO2022057787A1 (zh) 一类细胞程序性坏死抑制剂及其制备方法和用途
CN117430589A (zh) 2-氨基嘧啶类化合物或其盐及其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant